Week in Review: Fosun May Pay $350 Million for Second India Pharma Acquisition

Deals and Financings

• Shanghai Fosun Pharma is considering bidding $350 million for a 70% stake in India's Symbiotec Pharma, an API company;
• Zhejiang Huahai Pharma will float a $152 million bond offering to build a new biopharma facility in Hangzhou;
• Beijing's Global Health Drug Discovery Institute opened its doors earlier this year, backed by $100 million, including support from the Gates Foundation;
• Jacobson Pharma of Hong Kong raised $64 million in a private placement for M&A to expand its generics portfolio;

Trials and Approvals

• ImmunoMet Therapeutics, a US spinoff of Korea's HanAll Biopharma, began a Phase I trial of its lead candidate in solid tumor cancer patients.

Stock Symbols: (SHA: 600196; HK: 2196) (SHA: 600521) (HK: 2633) (KS: 009420)

Share this with colleagues:

Original Article: Week in Review: Fosun May Pay $350 Million for Second India Pharma Acquisition

More From BioPortfolio on "Week in Review: Fosun May Pay $350 Million for Second India Pharma Acquisition"

• Related Companies
• Related Events
• Related Clinical Trials
• Related PubMed Entries
• Related Medications